ABSTRACT
INTRODUCTION
Fetuses with congenital heart disease are at risk for postnatal adverse neurodevelopmental outcome. Despite advances in surgical and intensive care unit management, neurodevelopmental outcomes for individuals with hypoplastic left heart syndrome (HLHS) have remained unchanged over the past 20 years 1,2 . Compared with normal fetuses, fetuses with congenital heart disease have smaller brain volumes at birth, delayed maturation of the brain [3] [4] [5] [6] [7] [8] and are at higher risk of structural brain abnormalities 9 . In addition, studies have demonstrated that neonates with congenital heart disease have diminished preoperative cerebral blood flow 10 and a higher rate of periventricular leukomalacia (PVL) at birth, with significant increases in PVL observed after open heart surgery [11] [12] [13] . All of these differences may be secondary to diminished cerebral oxygen delivery to the brain 3 . Previous studies have shown that maternal hyperoxygenation (MH) increases fetal partial pressure of oxygen in the umbilical artery and vein, as well as umbilical arterial oxygen saturation [14] [15] [16] [17] . Therefore, we hypothesize that MH would increase cerebral oxygen delivery by increasing the partial pressure of oxygen within the fetus. As a neuroprotective agent, it may ameliorate some of the adverse metabolic events occurring in the fetal brain as a consequence of chronic hypoxemia that lead to white matter injury, delayed maturation and diminished brain volume.
The use of MH as a neuroprotective agent has not been investigated to date. In the third trimester, multiple complex processes, including expansion of the white matter, cortical folding and myelination, occur within the fetal brain 18 . In HLHS, we and other investigators have demonstrated previously that cerebrovascular resistance, as assessed via the Doppler-derived middle cerebral artery (MCA) pulsatility index (PI), is lower than in normal fetuses [19] [20] [21] [22] [23] , particularly in the third trimester 22 . This may occur in an autoregulatory manner to support the increased metabolic demands of the brain during this critical period of brain development in the third trimester of pregnancy 18 . In this observational study, we investigated MCA-PI in room air (RA) and after 10 min of MH in fetuses with HLHS. We aimed to determine how gestational age (GA) and/or baseline MCA-PI in RA might affect the response of cerebrovascular resistance to MH in fetuses with HLHS.
METHODS
The study population consisted of fetuses referred for echocardiography at our institution between January 2004 and September 2008 with HLHS (mitral stenosis/atresia and aortic stenosis/atresia) or HLHS variant (double outlet right ventricle with mitral and aortic stenosis/atresia or severely unbalanced atrioventricular canal with aortic stenosis/atresia). Subjects had been enrolled in a prospective observational study investigating the utility of MH to predict the need for urgent intervention on the atrial septum at birth in fetuses with HLHS or HLHS variant. All fetuses underwent serial echocardiography between 21 and 40 weeks' gestation according to an institutional review board approved protocol (IRB-2004-10-3948). Fetuses were scanned over the course of gestation according to a three-phase research protocol (baseline RA, MH and recovery in RA), as described previously 21 . During MH, mothers were administered 8 L of oxygen, delivered via a non-rebreather mask, which effectively provides a FiO 2 of 60%, for at least 10 min prior to obtaining the MCA Doppler signal 21 . All fetuses subsequently underwent a single ventricle palliation in the postnatal period. All mothers provided informed consent for their and their fetus' participation.
Inclusion criteria were singleton fetus with HLHS or HLHS variant, no extracardiac anatomical abnormality and normal umbilical artery Doppler flow patterns. Fetuses of mothers with diabetes mellitus, thyroid disorders or pre-eclampsia were excluded. Cerebrovascular resistance was assessed via the Doppler-derived MCA-PI, calculated as: (peak systolic velocity − end-diastolic velocity)/time-averaged mean velocity. MCA Doppler flow pattern was sampled with the mother in RA and after 10 min of MH. For each echocardiographic parameter, three measurements were made and averaged. All echocardiographic measurements were made using Syngo Dynamics v. 9 cardiovascular software package (Siemens Medical Solutions, Ann Arbor, MI, USA). Normal data were used to generate Z-scores for MCA-PI at baseline in RA and after 10 min of MH 24 .
Statistical analysis
Continuous baseline data were summarized using medians and interquartile range (IQR). MCA-PI in RA and after 10 min of MH, both the measured value and the Z-score, were explored graphically as a function of GA. Depending on the results of the models, the results were presented graphically using either a loess smoothing method to allow for non-linearity in the association, or a linear model. The association between GA and MCA-PI was quantified using a mixed-effects model. Both the original values and the Z-score in either RA (Z RA ) or after 10 min MH (Z MH ) were considered. The mixed-effects model takes into account the potential correlation between repeated measurements in some subjects. For each outcome variable, two models were considered, one that included a cubic spline to allow curvature in the association between variables and one that allowed a simple linear association. The simpler linear model was used unless a likelihood ratio (LR) test rejected the linear model in favor of the curvilinear model. The P-value is reported for the LR test if the cubic spline was chosen, or the hypothesis test of a zero slope if the linear model was chosen.
The change in MCA-PI Z-score after 10 min of MH compared with in RA ( Z ) was explored and analyzed as a function of either GA or baseline Z-score in RA.
Finally, modeling Z as a function of two predictors, the baseline Z-score in RA and/or GA was considered using eight different models. Four models included the predictors individually, modelled as a linear function or as a spline. The other four models included both predictors in all possible combinations of either linear terms or splines. The Bayesian information criterion (BIC) was used to suggest a 'best' model. Lastly, a receiver-operating characteristics (ROC) curve was determined based on an outcome of whether Z was positive (an increase in MCA-PI Z-score after 10 of min MH). The results for the models with the smallest BIC are reported. A 95% exact binomial confidence interval is reported for the original proportion of observations demonstrating a positive response to MH.
The type-I error rate was set to 0.05 throughout and all tests were two-sided. The analysis was carried out using statistical computing in R v. 3.3.0 (2016) using packages nlme, and pROC (R Core Team, R Foundation for Statistical Computing, Vienna, Austria; http://www.R-project.org/).
RESULTS
The study population comprised 43 fetal subjects. Of these, 38 had one or more measurements both at baseline in RA and following 10 min of MH. A total of 28 subjects had measurements at a single visit, six at two visits, eight at three visits and one at four visits. Median GA derived from fetal ultrasound measurement at enrollment was 28.7 (IQR, 25.5-32.6.) weeks and that based on last menstrual period (LMP) was 28.1 (IQR, 25.8-33.6) weeks. LMP-based GA was used for analysis as these data were complete for all subjects. At the first visit, median MCA-PI in RA was 1.76 (IQR, 1.59-1.98) and median MCA-PI Z-score (Z RA ) was −0.57 (IQR, −1.06 to 0.02). Due to technical issues conducting the measurements, two observations of MCA-PI in RA were missing and 10 observations of MCA-PI after 10 min of MH were missing. Figure 1a ,c demonstrates MCA-PI in fetuses with HLHS in RA, both the raw values and the Z-score (Z RA ), as a function of GA. In RA, the trend in the raw values showed significant curvature (P = 0.001, LR test, curvilinear vs linear model) with somewhat lower values at lower GA and a pronounced decline at higher GA. For the standardized values, mean Z RA declined in a linear fashion as a function of GA (P < 0.001, test of slope = 0). The equation describing the mean decline is:
In this equation, GA is 'centered' at week 28, so that a fetus with a GA of 28 has a value of 0 for the slope and the mean Z RA at 28 weeks is the intercept, a value of −0.47 (95% CI, −0.73 to −0.22, test of intercept = 0, P = 0.001). At a linear change in mean Z RA of −0.096 per week (95% CI, −0.13 to −0.06, test of slope = 0, P < 0.001), mean Z RA in fetuses with HLHS at 38 weeks is expected to be −1.44 (95% CI, −1.76 to −1.11), or almost 1.5 SD lower than expected for normal fetuses. The data confirm that MCA-PI in fetuses with HLHS is considerably lower than that of normally developing fetuses, and that the severity of the deficit increases with fetal age. Figure 1b,d shows MCA-PI in fetuses with HLHS after 10 min of MH, both the raw value and the Z-score (Z MH ) as a function of GA. In MH, the raw values again showed significant curvature (P = 0.002, LR test of curvilinear vs linear model), with somewhat lower values at younger GA and a more pronounced decline at older GA. Z MH was also curvilinear (P = 0.029). Using the model, mean Z MH at 28 weeks was −0.76 (95% CI, −1.16 to −0.36). At 38 weeks, mean Z MH was estimated to be −0.70 (95% CI, −1.18 to −0.23). These values remain significantly lower than those of normally developing fetuses. Figure 2 shows the change in Z-score for MCA-PI, Z , as a function of either GA or baseline Z RA . As a function We further explored whether Z RA alone, GA alone or a combination of the two variables would best explain the variation in Z (Table 1) . A model with Z RA alone was suggested, based on the smallest BIC. The BIC for this model was slightly smaller than for the model with both Z RA and GA and the term for GA did not achieve statistical significance (P = 0.13). Considering the change in MCA-PI, this result suggests that GA adds only a small amount of information beyond that provided by Z RA .
Using the model incorporating Z RA only, Table 2 Lastly, we considered an increase in Z (> 0 or < 0) as a binary outcome and constructed a ROC curve based on each model. In the original dataset, the proportion of observations with a positive Z was 59% (95% CI, 45-72%). The AUC for the model incorporating Z RA only was 0.756, just slightly smaller than the AUC of 0.777 for that incorporating Z RA and GA. This result suggests that the baseline Z RA has prognostic significance with respect to determining which subjects may respond to brief MH. It further confirms that fetal age has minimal prognostic significance beyond the information contained in Z RA . [19] [20] [21] [22] [23] , the current study demonstrated low cerebrovascular resistance in fetuses with HLHS, particularly in the third trimester 22 . In addition, cerebrovascular resistance, as assessed via MCA-PI, demonstrates a curvilinear relationship with MH in fetuses with HLHS similar to in fetuses with normal cardiovascular anatomy 24 . In both RA and after 10 min of MH, MCA-PI initially increases in the second trimester, peaks at around 25-30 weeks' gestation, and then falls steeply near term. In contrast, MCA-PI Z-score declines sharply in a linear fashion over the course of gestation, such that the mean MCA-PI Z-score for fetuses with HLHS is 1.4 standard deviations below normal values at 38 weeks' gestation.
DISCUSSION

Concordant with previous investigations
As shown in Figure 2 , MCA-PI first increases in response to MH at 28 weeks' gestation (intercept crossing 0 at this GA), suggesting that MH is more likely to be effective in increasing cerebrovascular resistance at or beyond 28 weeks' gestation. Our modeling suggests that, in fact, GA is largely a proxy for baseline MCA-PI. GA and MCA-PI in RA are correlated (Figure 1 ) and, individually, each is a predictor of improvement in MCA-PI response to MH (Figure 2) . However, when both variables are included in the model, the dominant variable is clearly MCA-PI in RA.
We also identified which fetuses with HLHS would be the best candidates in which to increase cerebrovascular resistance using short term MH. Fetuses with MCA-PI Z-scores lower than −0.58 tend to show positive increases in MCA-PI following MH. For those with MCA-PI Z-scores ≤ −0.96, the 95% CI excludes zero; in these fetuses, there is stronger evidence of a positive effect of MH. We hypothesize that an increase in MCA-PI toward normal values may correlate with better neurological values. In advance of this analysis, we proposed 28 weeks' gestation as the starting point for a future MH trial using chronic MH. While using the Z-score might yield better precision with respect to predicting increases in cerebrovascular resistance in response to MH, it is not practical to bring pregnant mothers repeatedly into the clinic to assess fetal Z-scores. The results of this study suggest that fetuses older than 28 weeks are more likely to have lower Z-scores and potentially benefit from MH. Use of gestational age to guide patient inclusion criteria for clinical trials may be implemented more readily than use of strict criteria based on Z-scores alone.
Whether increases or decreases in cerebrovascular resistance in response to MH are helpful or harmful to neurodevelopmental outcome remains to be determined. In normal fetuses, some studies have demonstrated an increase in cerebrovascular resistance in response to MH 25 , while others have demonstrated a decrease 26 . Therefore, given these conflicting results, it is difficult to make any direct comparisons between HLHS and normal fetuses with regard to these findings. However, we do not believe that the increase seen in response to MH is due to run-off into other vascular beds, since we demonstrated previously no change in umbilical artery PI in response to MH in fetuses with HLHS 21 . Similarly, Simchen et al. demonstrated no change in umbilical or uterine artery PI in response to MH in normal fetuses 26 . It is conceivable that the increase in cerebrovascular resistance in the third trimester could be due to run-off into the pulmonary vascular bed, since pulmonary vascular resistance decreases in the third trimester in HLHS fetuses with an unobstructed atrial septum 21 . However, if diminished pulmonary vascular resistance were responsible for this increase in cerebrovascular resistance, then one would expect that cerebrovascular resistance would increase for all fetuses with HLHS in the third trimester. However, Figure 2 demonstrates a heterogeneous response to MH in fetuses with HLHS. Those with MCA-PI Z-scores > −0.58 tended to have lower increases in cerebrovascular resistance in response to MH, even in the late third trimester, while fetuses with MCA-PI Z-scores < −0.58 tended to have higher increases in cerebrovascular resistance in response to MH, with the most dramatic increases seen for those with MCA-PI Z-score < −0.96. We hypothesize that HLHS fetuses with inadequate oxygen delivery to the brain undergo vasodilation of the cerebrovasculature in order to augment oxygen and nutritional delivery. Metabolic demands of the fetal brain are hypothesized to be the greatest during the third trimester since myelination, cortical folding and white matter development 18 occur at this time. Therefore, this might explain why changes in cerebrovascular resistance are most pronounced in the third trimester and do not occur earlier in gestation when oxygen delivery may be sufficient for fetal brain development. Autoregulatory compensation, however, is not complete, with multiple studies demonstrating smaller head circumferences [27] [28] [29] , greater brain immaturity [5] [6] [7] [8] and increased risk of periventricular luekomalacia 12, 13 in fetuses with HLHS compared with in normal fetuses. These data are consistent with the hypothesis that, as cerebral oxygen demand increases during the third trimester, oxygen delivery in fetuses with HLHS may be insufficient to meet this demand. Therefore, chronic MH therapy may serve as a useful means to increase oxygen delivery to the fetal brain, thereby improving the maturity and growth of the brain, as well as potentially protecting against the development of periventricular leukomalacia. However, we note that this study investigated only acute changes in cerebrovascular resistance with MH therapy. Whether HLHS fetuses would respond similarly to chronic MH remains to be determined.
We considered possible explanations for why the greatest increase in MCA-PI in response to MH was observed in HLHS fetuses with the lowest MCA-PI at baseline. We hypothesize that HLHS fetuses with higher MCA-PI Z-scores have adequate cerebrovascular oxygen and nutrient delivery to the fetal brain. These fetuses have no need to augment oxygen delivery to the brain. However, fetuses with inadequate cerebral oxygen delivery may be maximally vasodilated in order to increase oxygen delivery to the brain. In response to MH, cerebrovascular resistance increases toward normal values as a consequence of improved cerebral oxygen content of the blood. We hypothesize that this increase in cerebrovascular resistance in response to MH could allow for a safer transition to neonatal circulation and enhanced neuroprotection.
Prospective trials are needed to investigate the utility of chronic MH as a neuroprotective agent. As we move towards innovative research into the utility of MH as a neuroprotective agent in fetuses with HLHS, our study may prove valuable for the design of future studies. Importantly, we note little improvement in cerebrovascular resistance for HLHS fetuses with baseline MCA-PI Z-scores > −0.58 or prior to 28 weeks' gestation.
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